Why the Market Dipped But Astrazeneca (AZN) Gained Today
Yahoo · 14 de sept de 2026
In the latest trading session, Astrazeneca (AZN) closed at $163.78, marking a +2.25% move from the previous day.
CEDEAR AZN
Astrazeneca Plc
Sí, existe CEDEAR de AZN en Argentina. Operás bajo el ticker AZN en BYMA, con ratio 4:1 respecto a la acción en NYSE.
Empresa subyacente
HealthcareDrug Manufacturers - General
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications; and Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
- País
- United Kingdom
- Empleados
- 96.100
- Sitio web
- astrazeneca.com
Precio histórico
Últimos 198 días · 12/11/25 — 14/09/26
+1.28%
Cotización y datos
NYSERatio 4:1 · Subyacente AZN
CEDEAR (ARS)
Precio
$ 65.250
Var. %
-0,19%
Volumen operado
7.683
Subyacente (USD)
Precio AZN
US$ 163,60
Teórico (precio / ratio)
AZN ÷ 4
US$ 40,90
Dólar MEP (AZND)
Preguntas frecuentes
¿Existe CEDEAR de AZN en Argentina?
Sí, existe el CEDEAR de AZN (Astrazeneca Plc) en la Bolsa de Comercio de Buenos Aires (BYMA). Su ticker local es AZN.
¿Cuál es el ticker del CEDEAR de Astrazeneca Plc?
El ticker del CEDEAR de Astrazeneca Plc en Argentina es AZN. La acción subyacente cotiza en NYSE con el símbolo AZN.
¿Cuál es el ratio del CEDEAR AZN?
El CEDEAR AZN tiene un ratio de 4:1. Eso significa que 4 CEDEARs equivalen a 1 acción de AZN.
¿Cuánto vale el CEDEAR AZN hoy?
El CEDEAR AZN cotiza hoy a $ 65.250 en pesos argentinos, con una variación diaria de -0,19%.
¿Cuánto vale la acción AZN en dólares?
La acción subyacente AZN (Astrazeneca Plc) cotiza a US$ 163,60 en su mercado de origen (NYSE).
Noticias
AstraZeneca’s cancer pipeline posts two wins and a loss
Yahoo · 14 de sept de 2026
The UK-Swedish pharma giant has shared readouts from key portfolio assets such as Enhertu, Tagrisso and Etcamah.
AZN's Etcamah Fails Late-Stage Study for First-line Breast Cancer
Yahoo · 14 de sept de 2026
AstraZeneca's Etcamah fails to improve PFS significantly in a phase III first-line breast cancer study, while its approved use remains unaffected.